Medical physics

High Q Technologies Inc. Hires Vice President, Research and Development and Announces Additional Recent Appointments to Support Rapid Growth

Retrieved on: 
Wednesday, September 7, 2022
Product, VP, University, Engineering, EPR, Technology, CEO, Â, High Q, Blackberry, Louisiana State University, Audit, Medical physics, Product management, Tulane University, Master of Finance, PerkinElmer, Creativity, MBA, GLOBE, Ayaz, Therapy, Doctor of Philosophy, NDI, Chemical engineering, Specialization, Drug discovery, Marketing, PMP, Neurosurgery, Research and development, Environment, Development, Systems engineering, University of Derby, Management, Western University, Research, Leadership

He is an accomplished technology leader with over 20 years of experience in product development, pre-clinical research, and business development.

Key Points: 
  • He is an accomplished technology leader with over 20 years of experience in product development, pre-clinical research, and business development.
  • Before High Q, Andrew was Director of Research and Development at NDI overseeing new product development, early-stage technology research, and sustaining engineering for in-market products.
  • I am extremely pleased to be joining High Q Technologies at such a pivotal time in the companys growth trajectory.
  • I am eager to work with the leadership team and our associates to build scalable processes that support our rapid global growth.

Travelers Financial Group Announces Ashwin Pamidi as CFO and Head of Corporate Strategy

Retrieved on: 
Wednesday, August 24, 2022
University, Rotman School of Management, Traveler, View, Doctor of Philosophy, Solution, Medical physics, Strategic management, CIBC World Markets, Principal Financial Group, Multimedia, National bank, CFO, McMaster University, MBA, National Bank of Canada, Management, Science, BC

VANCOUVER, BC, Aug. 24, 2022 /PRNewswire/ -Travelers Financial Group is one of the leaders in a wide spectrum of consumer and commercial financing related businesses in Canada and United States, today announced that Ashwin Pamidi has been named as Chief Financial Officer and Head of Corporate Strategy.

Key Points: 
  • VANCOUVER, BC, Aug. 24, 2022 /PRNewswire/ -Travelers Financial Group is one of the leaders in a wide spectrum of consumer and commercial financing related businesses in Canada and United States, today announced that Ashwin Pamidi has been named as Chief Financial Officer and Head of Corporate Strategy.
  • In the past, Ashwin has held senior positions with National Bank Financial and CIBC World Markets.
  • "We are very pleased to welcome Ash at Travelers as the newest member of the executive team," said Jim Case, Chief Executive Officer, Travelers Financial Group.
  • "I am honored to be joining the Travelers Financial Group as a new CFO and Head of Corporate Strategy," said Ashwin Pamidi.

MedAustron becomes first center in the world to use RayCommand to treat patients

Retrieved on: 
Wednesday, May 18, 2022
Helium, University, Nasdaq Stockholm, OAS, Electron, Ion, RaySearch Laboratories, OIS, HDR, Patient, Research, Efficiency, Carbon, TPS, Karolinska Institute, Partnership, Photon, Safety, Medical physics, Proton, Cancer, TCS, CEO, Medical imaging, Medical device, Pharmaceutical industry

Through this milestone MedAustron also becomes the first oncology center where RayStation*, RayCare* and RayCommand are used together to treat patients.

Key Points: 
  • Through this milestone MedAustron also becomes the first oncology center where RayStation*, RayCare* and RayCommand are used together to treat patients.
  • RaySearch and MedAustron have been collaborating since 2012, when MedAustron was RaySearch's first customer for carbon ion therapy treatment planning in RayStation.
  • When MedAustron recently took first RayCare and then RayCommand in clinical use a big milestone was reached.
  • Markus Stock, Head of Medical Physics at MedAustron, says: "MedAustron has already been collaborating successfully with RaySearch for more than 10 years.

DetectedX Launches Radiology Online Learning Platform to the U.S. Market at SBI

Retrieved on: 
Wednesday, May 11, 2022
Online, Radiology, COVID-19, Continuing medical education, Lung cancer, University, GE Healthcare, Mammography, Health, Woman, CME, Breast cancer, Self-assessment, Breast, Review, 2D, Lung, Radiation, Fujifilm, Artificial intelligence, SBI, Medical imaging, Publication, Marketing, Classification, Education, Tomosynthesis, Educational technology, Medical physics, University of Sydney, Research, CEO, Multimedia

SAVANNAH, Ga., May 11, 2022 /PRNewswire/ -- DetectedX announced today that it will launch its Radiology Online Learning Platform to radiologists in the United States at the SBI/ACR Breast Imaging Symposium 2022, in Savannah, GA, May 16-19 (Booth #221). Designed to improve radiologists' ability to correctly detect breast lesions in 2D and 3D Mammography, the online self-assessment modules have been shown to improve cancer detection by over 34 percent. 

Key Points: 
  • The new learning tools will feature new breast and lung educational content, as well as Medical Physics, Radiation and Artificial Intelligence topics.
  • "The online mammographic test sets available through DetectedX are invaluable to the education of radiologists and trainees," said Dianne Georgian-Smith MD, FSBI, FACR.
  • "Our ultimate goal with the Radiology Online Learning Platform is to help radiologists diagnose breast cancer faster and more accurately, giving women worldwide a better chance of cancer survival."
  • DetectedX's Radiology Online Learning Center, focusing on diagnostic accuracy and driven by artificial intelligence, is revolutionizing disease detection in 150 countries.

Sun Nuclear Highlights New SunSCAN™ 3D System & Smart Quality Management Solutions at ESTRO 2022

Retrieved on: 
Thursday, May 5, 2022
Cloud, Yellow Sun (nuclear weapon), Patient safety, Quality management, NYSE, QA, Cancer, Radiation, Hall, Medical imaging, Adoption, Diagnosis, Sale, Congress, CIRS, ATOM, Software as a service, MIR, Solution, Technology, Medical physics, CEO, Radiation therapy, 3D, Multimedia, Renewable energy

MELBOURNE, Fla., May 5, 2022 /PRNewswire/ -- Sun Nuclear Corporation (Sun Nuclear), a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), will feature its comprehensive solutions portfolio for independent, integrated Quality Management of Radiation Therapy and Diagnostic Imaging at the ESTRO 2022 Congress, held May 6-10 in Copenhagen, Denmark. ESTRO will mark the first live showing of the new SunSCAN™ 3D Cylindrical Water Scanning System. Throughout ESTRO in the Sun Nuclear booth (Hall C 1010), the company will feature: the SunSCAN 3D System; SunCHECK™ Platform; new CIRS solutions joining the Sun Nuclear portfolio; expanded offerings for stereotactic and MR-guided treatments; and a series of educational presentations and product demonstrations.

Key Points: 
  • ESTRO will mark the first live showing of the new SunSCAN 3D Cylindrical Water Scanning System .
  • The new SunSCAN 3D System will be revealed at 18:05 during the ESTRO opening reception and will be on display in the Sun Nuclear booth throughout ESTRO.
  • CIRS extends the Sun Nuclear Quality Management offering with renowned tissue simulation technology, anthropomorphic phantoms, and comprehensive testing and verification solutions.
  • ESTRO attendees are invited to join the Sun Nuclear satellite symposium, Smarter Quality Management: Innovations & Insights, on May 8, beginning at 13:00 in auditorium 11, for highlights on the latest advancements for Quality Management.

Sun Nuclear Highlights New SunSCAN™ 3D System & Smart Quality Management Solutions at ESTRO 2022

Retrieved on: 
Thursday, May 5, 2022
Cloud, Yellow Sun (nuclear weapon), Patient safety, Quality management, NYSE, QA, Cancer, Radiation, Hall, Medical imaging, Adoption, Diagnosis, Sale, Congress, CIRS, Software as a service, MIR, Solution, Technology, Medical physics, CEO, Radiation therapy, 3D, Renewable energy

MELBOURNE, Fla., May 5, 2022 /PRNewswire/ -- Sun Nuclear Corporation (Sun Nuclear), a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), will feature its comprehensive solutions portfolio for independent, integrated Quality Management of Radiation Therapy and Diagnostic Imaging at the ESTRO 2022 Congress, held May 6-10 in Copenhagen, Denmark. ESTRO will mark the first live showing of the new SunSCAN™ 3D Cylindrical Water Scanning System. Throughout ESTRO in the Sun Nuclear booth (Hall C 1010), the company will feature: the SunSCAN 3D System; SunCHECK™ Platform; new CIRS solutions joining the Sun Nuclear portfolio; expanded offerings for stereotactic and MR-guided treatments; and a series of educational presentations and product demonstrations.

Key Points: 
  • ESTRO will mark the first live showing of the new SunSCAN 3D Cylindrical Water Scanning System .
  • The new SunSCAN 3D System will be revealed at 18:05 during the ESTRO opening reception and will be on display in the Sun Nuclear booth throughout ESTRO.
  • CIRS extends the Sun Nuclear Quality Management offering with renowned tissue simulation technology, anthropomorphic phantoms, and comprehensive testing and verification solutions.
  • ESTRO attendees are invited to join the Sun Nuclear satellite symposium, Smarter Quality Management: Innovations & Insights, on May 8, beginning at 13:00 in auditorium 11, for highlights on the latest advancements for Quality Management.

Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer

Retrieved on: 
Tuesday, May 3, 2022
Biotechnology, General Health, Pharmaceutical, Health, Protein engineering, Department, University, Seismology, Assistant director, Merck & Co., Biotechnology, Merck, Patient, McGill University, Doctor of Philosophy, Partnership, Acquisition, Program, FDA, Medical physics, Degenerative disease, Business development, Bachelor of Science, Machine learning, IP, Goal, BMS, CEO, Growth, Multimedia, Pharmaceutical industry, Management, Biochemistry

Seismic Therapeutic, Inc. , a biotechnology company advancing machine learning for immunology drug development, today announced the appointment of Maude Tessier, PhD, as Chief Business Officer.

Key Points: 
  • Seismic Therapeutic, Inc. , a biotechnology company advancing machine learning for immunology drug development, today announced the appointment of Maude Tessier, PhD, as Chief Business Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220503005370/en/
    We are very pleased to welcome Maude to the Seismic leadership team.
  • Seismic is in a period of significant growth and Maude will play a vital role in implementing and executing our long-term business, partnering and financing strategy.
  • Dr. Maude Tessier joins Seismic after serving as Chief Business Officer of Ikena Oncology (Nasdaq: IKNA), a clinical-stage biotech company, where she built and managed the business development, legal and corporate strategy functions.

Sun Nuclear Introduces SunSCAN™ 3D,Next-Generation Cylindrical Water Scanning System

Retrieved on: 
Tuesday, May 3, 2022
European Society for Medical Oncology, SRS, Yellow Sun (nuclear weapon), Patient safety, Quality assurance, Quality management, NYSE, Sun, Prevalence, QA, Cancer, Radiation, Medical imaging, Radiation therapy, Adoption, Diagnosis, Sale, Orientation, Medical physics, MIR, Technology, SBRT, Quality, Foundation, 3D

MELBOURNE, Fla. , May 3, 2022 /PRNewswire/ -- Sun Nuclear Corporation (Sun Nuclear), a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), today announced the release of the SunSCAN™ 3D cylindrical water scanning system for linear accelerator (linac) commissioning, beam scanning and annual Quality Assurance (QA) in Radiation Therapy. The SunSCAN 3D water scanning system is the latest addition to Sun Nuclear's comprehensive solutions portfolio for independent, integrated Quality Management of Radiation Therapy and Diagnostic Imaging.

Key Points: 
  • MELBOURNE, Fla., May 3, 2022 /PRNewswire/ -- Sun Nuclear Corporation (Sun Nuclear), a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), today announced the release of the SunSCAN 3D cylindrical water scanning system for linear accelerator (linac) commissioning, beam scanning and annual Quality Assurance (QA) in Radiation Therapy.
  • The SunSCAN 3D water scanning system is the latest addition to Sun Nuclear's comprehensive solutions portfolio for independent, integrated Quality Management of Radiation Therapy and Diagnostic Imaging.
  • Building on the capabilities of the groundbreaking Sun Nuclear 3D SCANNER water tank, released in 2011 and with more than 1,000 units in use, the SunSCAN 3D water scanning system introduces faster, easier workflows and hyper-accurate dosimetry.
  • Based on a decade of experience with our legacy water tank, we've made the new SunSCAN 3D water scanning system easier and faster for every user in the Medical Physics department," noted Eric Schloesser, Sun Nuclear President.

Sun Nuclear Introduces SunSCAN™ 3D, Next-Generation Cylindrical Water Scanning System

Retrieved on: 
Tuesday, May 3, 2022
European Society for Medical Oncology, SRS, Yellow Sun (nuclear weapon), Patient safety, Quality assurance, Quality management, NYSE, Sun, Prevalence, QA, Cancer, Radiation, Medical imaging, Radiation therapy, Adoption, Diagnosis, Sale, Orientation, Medical physics, MIR, Technology, SBRT, Quality, Foundation, 3D

MELBOURNE, Fla., May 3, 2022 /PRNewswire/ -- Sun Nuclear Corporation (Sun Nuclear), a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), today announced the release of the SunSCAN™ 3D cylindrical water scanning system for linear accelerator (linac) commissioning, beam scanning and annual Quality Assurance (QA) in Radiation Therapy. The SunSCAN 3D water scanning system is the latest addition to Sun Nuclear's comprehensive solutions portfolio for independent, integrated Quality Management of Radiation Therapy and Diagnostic Imaging.

Key Points: 
  • MELBOURNE, Fla., May 3, 2022 /PRNewswire/ -- Sun Nuclear Corporation (Sun Nuclear), a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), today announced the release of the SunSCAN 3D cylindrical water scanning system for linear accelerator (linac) commissioning, beam scanning and annual Quality Assurance (QA) in Radiation Therapy.
  • The SunSCAN 3D water scanning system is the latest addition to Sun Nuclear's comprehensive solutions portfolio for independent, integrated Quality Management of Radiation Therapy and Diagnostic Imaging.
  • Building on the capabilities of the groundbreaking Sun Nuclear 3D SCANNER water tank, released in 2011 and with more than 1,000 units in use, the SunSCAN 3D water scanning system introduces faster, easier workflows and hyper-accurate dosimetry.
  • Based on a decade of experience with our legacy water tank, we've made the new SunSCAN 3D water scanning system easier and faster for every user in the Medical Physics department," noted Eric Schloesser, Sun Nuclear President.

Medtech: Braintale Announces the Launch of Its Digital Platform Dedicated to the Monitoring and Prediction of Neurological Disorders

Retrieved on: 
Wednesday, March 16, 2022
Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Medical Devices, Clinical Trials, Software, Neurology, Doctor of Philosophy, Prognosis, Solution, Alzheimer's disease, Magnetic resonance imaging, Neuroimaging, Health, Patient, The Lancet, ISO, MDR, Hospital, IIA, Traumatic brain injury, Risk, Medical Device Regulation Act, Diagnosis, Charcot disease, MRI, Brain, Lists of diseases, Ageing, Pioneer, Caregiver, Use, Biomarker, ICU, Neuroradiology, Medtech, White matter, Cardiac arrest, CEO, Intensive Care Medicine (journal), Physician, ESPCI, American Hospital of Paris, Welfare, Medical physics, Trauma, HIV disease progression rates, Coma, Neuroscience, DTI, Medical imaging, Pharmaceutical industry, Medical device, Software as a service, Braintale, LallianSe, BRAINTALE, LALLIANSE

Braintale, the cerebral white matter specialist French medtech, announces today the launch of the brainTale-care platform with its modules brainQuant, dedicated to white matter quantification, and brainScore-coma, offering the prediction of coma recovery.

Key Points: 
  • Braintale, the cerebral white matter specialist French medtech, announces today the launch of the brainTale-care platform with its modules brainQuant, dedicated to white matter quantification, and brainScore-coma, offering the prediction of coma recovery.
  • Importantly, the predictive score extracted from white matter in brain-damaged coma patients provides a precise prediction to guide doctors and families in their decision-making.
  • Since its creation in 2018, Braintale has been developing clinically accessible, effective and validated measurement and prediction digital platforms for physicians treating patients with brain injuries.
  • Braintale is an innovative company dedicated to deciphering white matter to enable better care in neurology and intensive care with clinically validated prognostic solutions.